Related Experiment Video
Updated: Aug 19, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Altered expression of TGF-beta receptors in hepatocellular carcinoma--effects of a constitutively active TGF-beta
Annemarie Musch1, Christian Rabe, Mignon-Denise Paik
1Department of Medicine I, University of Bonn, Germany.
Background/Aims:
Hepatocellular carcinomas (HCC) often show resistance to the effects of transforming growth factor-beta (TGF-beta). This study focuses on molecular mechanisms of this resistance to explore ways to overcome it.
Methods:
Transcription and protein expression of TGF-beta type I and type II receptors (TGF-betaRI/RII) were analyzed in clinical HCCs and the human hepatoma cell lines HuH-7 and HepG2. HuH-7 cells were transiently and stably transfected with a constitutively active TGF-betaRI mutant (CA TGF-betaRI). Resulting growth kinetics, integrin expression, invasiveness, TGF-beta-mediated activation of human plasminogen activator inhibitor type-1 (PAI-1) promoter and Smad expression were determined.
Results:
In clinical HCCs, there was less TGF-betaRII (6/10 cases) and more TGF-betaRI (8/10 cases) protein expression detectable in tumor compared to adjacent liver tissue. In HuH-7 cells, TGF-betaRII expression was likewise decreased. Cells transiently transfected with CA TGF-betaRI exhibited strong TGF-beta-related PAI-1 promoter activation. Stably transfected cells showed an attenuated response of the PAI-1 promoter, but increased Smad7 expression. Proliferation of stable clones was decreased. There was no change in integrin expression or invasiveness.
Conclusions:
Decreased TGF-betaRII protein expression might cause TGF-beta resistance in a subset of clinical HCCs. Stable transfection with CA TGF-betaRI reverses this in HuH-7 cells without increasing invasiveness.
Insights
Hepatocellular carcinoma (HCC) resistance to transforming growth factor-beta (TGF-beta) may stem from reduced TGF-beta receptor II (TGF-betaRII) expression. Restoring TGF-beta receptor I (TGF-betaRI) function in HCC cells decreased proliferation without increasing invasiveness.
Area of Science:
- Hepatocellular carcinoma (HCC) research
- Molecular mechanisms of cancer resistance
- TGF-beta signaling pathway
Background:
- Hepatocellular carcinoma (HCC) frequently exhibits resistance to transforming growth factor-beta (TGF-beta) signaling.
- Understanding the molecular basis of this resistance is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the molecular mechanisms underlying TGF-beta resistance in HCC.
- To explore strategies for overcoming TGF-beta resistance in HCC.
Main Methods:
- Analyzing TGF-beta type I and type II receptor (TGF-betaRI/RII) expression in clinical HCCs and hepatoma cell lines (HuH-7, HepG2).
- Transfecting HuH-7 cells with a constitutively active TGF-betaRI mutant (CA TGF-betaRI).
- Assessing growth kinetics, integrin expression, invasiveness, PAI-1 promoter activation, and Smad expression in transfected cells.
Main Results:
- Clinical HCCs showed altered TGF-betaRI/RII protein expression compared to adjacent liver tissue.
- HuH-7 cells with decreased TGF-betaRII expression exhibited resistance.
- Stable transfection with CA TGF-betaRI in HuH-7 cells attenuated PAI-1 promoter response, increased Smad7 expression, and decreased proliferation without affecting invasiveness.
Conclusions:
- Reduced TGF-betaRII protein expression may contribute to TGF-beta resistance in a subset of HCC.
- Stable expression of CA TGF-betaRI can reverse TGF-beta resistance in HCC cells, offering a potential therapeutic avenue without enhancing invasiveness.
Related Concept Videos
TGF - β Signaling Pathway
Cirrhosis II: Pathophysiology
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...

